Psychotherapeutic benefits of opioid agonist therapy (Q34014407)

30 July 2017

1 reference

title

Psychotherapeutic benefits of opioid agonist therapy (English)

1 reference

30 July 2017

0 references

Peter L Tenore

1

1 reference

30 July 2017

1 January 2008

1 reference

Journal of Addictive Diseases

30 July 2017

1 reference

30 July 2017

27

1 reference

30 July 2017

3

1 reference

30 July 2017

49-65

1 reference

Enkephalin may mediate euphoria and drive-reduction reward

30 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Regionally selective increases in mu opioid receptor density in the brains of suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Possible involvement of endorphin withdrawal or imbalance in specific premenstrual syndromes and postpartum depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Possible antidepressive effects of opioids: action of buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Buprenorphine treatment of refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Buprenorphine responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Depressive symptoms during buprenorphine treatment of opioid abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The relationship between mood state and plasma methadone concentration in maintenance patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Possible antidepressant activity of methadone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

PET imaging of serotonin 1A receptor binding in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Reduced serotonin type 1A receptor binding in panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The effect of sertraline on methadone plasma levels in methadone-maintenance patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Glutamate and depression: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

21 January 2018

Glutamate and anxiety

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Glutamate, GABA, glycine and taurine modulate serotonin synthesis and release in rostral and caudal rhombencephalic raphe cells in primary cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Chronic treatment with antidepressant drugs reversibly alters NMDA mediated regulation of extracellular 5-HT in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Mu-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Psychiatric comorbidity in methadone maintained patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Predictors of retention in methadone programs: a signal detection analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Methadone dosage and retention: an examination of the 60 mg/day threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Retention in a low-threshold methadone maintenance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Determining effective methadone doses for individual opioid-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

The Fifth Edition of the Addiction Severity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Antidepressant treatment in methadone maintenance patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Medical care for injection-drug users with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

Worsening of obsessive–compulsive symptoms under methadone tapering

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10550880802122646

10.1080/10550880802122646

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

18956529